Abstract: An aviation gasoline composition having: from about 70 vol % to about 80 vol % isooctane; from about 5 vol % to about 9 vol % isopentane; from about 10 vol % to about 20 vol % of one or more dialkyl ether; and from about 1 vol % to about 5 vol % of one or more alcohol, from about 0.02 vol % to about 0.07 vol % of one or more octane enhancer such as MMT, and, optionally, one or more additives selected from the group consisting of: antioxidants, anti-icing agents, antistatic additives, corrosion inhibitors, dyes, lubricants, and mixtures thereof, wherein the aviation gasoline has a motor octane number of at least 99.6.

Abstract: The present invention relates to a method for producing agglomerates from a feedstock comprising at least one biomass stream, the method comprising the steps of: combining the feedstock with one or more binding reagents; and introducing the feedstock into an agglomeration apparatus in the presence of a polymerisation activator to produce the agglomerates.

Abstract: Disclosed are novel engineered fuel feed stocks, feed stocks produced by the described processes, and methods of making the fuel feed stocks. Components derived from processed. MSW waste streams can be used to make such feed stocks which are substantially free of glass, metals, grit and noncombustibles. These feed stocks are useful for a variety of purposes including co-firing with coal and as substitutes for coal.

Abstract: Provided is lubricating oil composition including from 10 to 90 wt % of a base stock comprising a C28-C32 hydrocarbon fraction (“dimers”) and optionally a C42-C48 hydrocarbon fraction (“trimers”) produced by oligomerization of a linear C14 mono-olefin, a linear C16 mono-olefin, or a mixture thereof, in the presence of a Lewis acid catalyst, and the remainder of the composition including one or more lubricating oil additives. The lubricating oil composition provides an oxidative stability of greater than 100 hours (time to 200% KV@40 deg. C. increase) and a mini traction machine (MTM) average traction coefficient at 100 deg. C. of less than 0.0081.

Abstract: The present invention provides a lubricant composition comprising a base oil of lubricating viscosity, wherein the base oil comprises an ether base stock of formula (A) where: Ra and Rb are aliphatic hydrocarbyl groups and may be the different; the lubricant composition further comprising from 0.5 to 7% of total dispersant additive, by weight of the lubricant composition. In some embodiments, the ether base stock has the formula (1) where: R1, R2, R3, R4, R5 and R6 are as defined herein. The lubricant composition may be used for lubricating a surface in an internal combustion engine as well as for improving the fuel economy performance and/or piston cleanliness performance of an engine and/or a vehicle, such as an automotive vehicle associated with an internal combustion engine.

Abstract: The present invention provides a lubricant composition comprising a base oil of lubricating viscosity, wherein the base oil comprises an ether base stock of formula (A), where: Ra and Rb are aliphatic hydrocarbyl groups and may be the same or different; the lubricant composition further comprising at least one aminic anti-oxidant and at least one phenolic anti-oxidant. In some embodiments, the ether base stock has the formula (1), where: R1 R2, R3, R4, R5 and R6 are as defined herein. The lubricant composition may be used for lubricating a surface in an internal combustion engine as well as for improving the fuel economy performance and/or piston cleanliness performance of an engine and/or a vehicle, such as an automotive vehicle associated with an internal combustion engine.

Abstract: The present application relates to a lubricant composition comprising: at least one base oil; from 0.05 to 1.5% by weight of an organomolybdenum compound; and from 0.005 to 1% by weight of TiO2 particles.

Abstract: A cleaning solution for a turbine engine includes water within a range between about 68.65 percent and about 99.63 percent by volume of the cleaning solution; a first organic acidic component within a range between about 0.1 percent and about 15 percent by volume of the cleaning solution; wherein the organic acid comprises citric acid; a second organic acidic component within a range between about 0.1 percent and about 15 percent by volume of the cleaning solution; wherein the organic acid comprises glycolic acid; isoropylamine sulphonate within a range between about 0.07 percent and 0.14 percent by volume of the cleaning solution; alcohol ethoxylate within a range between about 0.035 percent and 0.07 percent by volume of the cleaning solution; triethanol amine within a range between about 0.035 percent and 0.07 percent by volume of the cleaning solution; sodium lauriminodipropionate within a range between about 0.03 percent and 1.0 percent by volume of the cleaning solution.

Abstract: Pouches, for example pouches that contain one or more active agents, such as a fabric care active agent or dishwashing active agent and/or detergent compositions, and more particularly pouches employing a water-soluble fibrous wall material, pouches employing a fibrous wall material that ruptures during use, and methods for making same, are provided.

Abstract: An in-the-bowl (ITB) toilet cage contains multiple pieces of a solid toilet block composition coated with silica

Abstract: The present disclosure is directed to wipes that include aqueous compositions and methods for coating, particularly protecting and optionally cleaning, surfaces, particularly metallic surfaces.

Abstract: A beverage making pack according to an embodiment of the present disclosure may include a flexible container having a beverage making space, a pack body to which the flexible container is coupled and which has a pack opening communicating with the beverage making space and a seating part seated on a fermentation tank module, a tube connected to a lower portion of the pack body and accommodated in the flexible container, and a cap configured to open/close the pack opening.

Abstract: Described herein are devices, systems, and methods to aid in the manipulation of cells. The devices, methods, and systems disclosed herein can be applied towards, for example, automation of the in vitro fertilization process.

Abstract: The present disclosure relates to equipment and a method for additive manufacturing, comprising an orientable energy excitation means for generating intermittent interaction with a fluid covering a blade in order to trigger a jet oriented in the direction of a target, the fluid consisting of a liquid vector containing inhomogeneities, wherein: the fluid forms a liquid film of a thickness measuring less than 500 ?m on a blade having at least one area allowing the interaction with the laser, into which at least one inlet leads, the interaction area leading into at least one outlet, the equipment also comprising means for the circulation of the fluid between the inlet and the outlet.

Abstract: The invention describes a methodology for production of a secondary extra-particle fungal matrix for application as a mycological material, manufactured via a Type II actively aerated static packed-bed bioreactor. A pre-conditioned air stream is passed through a substrate of discrete elements inoculated with a filamentous fungus to form an isotropic inter-particle hyphal matrix between the discrete elements. Continued feeding of the air through the substrate of discrete elements and isotropic inter-particle hyphal matrixes develops an extra-particle hyphal matrix that extends from an isotropic inter-particle hyphal matrix in the direction of airflow into a void space within the vessel.

Abstract: A filtration method for filtration of nucleated cells that includes providing a filter containing at least one of a metal and a metal oxide as a major component thereof and having a plurality of through-holes therein, and passing a liquid containing the nucleated cells through the filter. The diameter of an inscribed circle of each of the plurality of through-holes is smaller than the size of the nuclei of the nucleated cells, and the inscribed circle of each of the plurality of through-holes touches all sides defining an opening of the through-hole.

Abstract: A picktool manipulator device collects a specimen from a culture medium. In a first mode of operation, a picktool is allowed to move in an axial direction relative to support structure of the device. A detector may generate a signal in response to movement of the body in the axial direction so as to determine a height at which the picktool contacts the medium. The device may operate in the first mode when collecting a specimen from a culture medium. A second mode of operation constrains or precludes axial movement of the picktool. In some cases, the device may operate in the second mode when receiving a new picktool or discarding a used picktool.

Abstract: A cell sorting method includes: obtaining a cervical sample of a pregnant mammal, the cervical sample including placental trophoblast cells and cervical cells; removing the mucus of the cervical sample; dispersing the placental trophoblast cells and the cervical cells; centrifuging the cervical sample to remove the supernatant of the cervical sample; and using a dielectrophoretic chip to perform sorting on the cervical sample, so as to sort out the placental trophoblast cells from the cervical cells.

Abstract: The disclosure relates to an AFFT2 cell and a preparation method thereof. According to an embodiment, the cell is transformed with the TCR-T technology. The transformed T cells are blocked in vitro by an antibody drug of suppressive signaling molecules. According to another embodiment, a predicted antigen epitope is centered on a mutant amino acid site, the predicted antigen epitope extends 10 amino acids to each side of the mutant amino acid site, and the predicted antigen epitope serves as a potential antigen epitope. According to a further embodiment, TCR genes in a peripheral blood cell of a patient are knocked out by a CRISPR technology.

Abstract: The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells.

Abstract: Compositions and methods for manufacturing induced immune regulatory cells comprising induced myeloid suppressive cells including MDSCs (myeloid-derived suppressor cells), dendritic cells, macrophages, and subpopulations thereof are provided. Also provided are methods and compositions for further modifying and modulating the induced immune regulatory cells to achieve enhanced therapeutic potential in treating autoimmune disorders, hematological malignancies, solid tumors, viral infections, neurodegenerative disorders, inflammatory conditions, or GvHD.

Abstract: Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.

Abstract: The described invention provides a method for in vitro immunoactivation of mononuclear cells by contact with one or more populations of engineered leukocyte stimulator cells genetically engineered to express a core of 3 essential immunomodulator peptides, and optionally additional R immunomodulator peptides, and use of a cell product comprising the expanded and activated mononuclear cell population comprising one or more subpopulations of cytotoxic serial killer cells for passive immunization of a cancer patient not currently under the influence of an immunosuppressive regimen.

Abstract: The present invention relates to a method for irradiating a population of mammalian cells comprising at least one target mammalian cell with electron beams and/or X-rays, characterized in that: (i) a composition comprising a population of mammalian cells is irradiated in vitro with electron beams and/or X-rays, the population of mammalian cells containing at least one target mammalian cell and the dose rate being within the range from 5 Gy/sec to 107 Gy/sec, and (ii) optionally viable target mammalian cells are isolated or enriched from the population of mammalian cells, and to agents obtainable thereby and to uses thereof.

Abstract: The present invention is directed to compositions and methods to increase the expression of PD-L1 and/or IDO-1 in a population of cells, the modulated cells expressing increased PD-L1 and/or IDO-1, and methods related to the immunosuppressive effects obtained by cells expressing increased PD-L1 and/or IDO-1.

Abstract: A method for producing a cell culture containing desired cells is provided. The desired cells are induced to be differentiated from pluripotent stem cells. The method includes seeding a cell population by dispersing embryoid bodies obtained by inducing differentiation from the pluripotent stem cells to the desired cells. The embryoid bodies are dispersed at a density reaching confluence or higher.

Abstract: Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1+ cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscie myosin II inhibitor.

Abstract: A gut organoid includes a tissue structure that encloses a cavity. A method of using the gut organoid includes providing a test drug to the gut organoid in the presence of a buffer solution so that liquid comprising the test drug enters into the cavity, and collecting and analyzing the liquid in the cavity. A method for producing the gut organoid includes plating cells on a cell culture substrate including a surface on which a cell-adhesive region and a non-cell-adhesive region surrounding the cell-adhesive region are formed, and culturing the cells plated on the cell culture substrate so as to induce differentiation of the cells.

Abstract: The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one Plasmodium antigen. The Plasmodium antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof.

Abstract: Described herein are compositions relating to alphavirus-based virus-like particles (VLPs) and methods for making and using the described VLPs. The described compositions include VLPs and vectors and cells used to produce the VLPs. Also included are related methods to produce the VLPs, to transduce cells using the VLPs, and to produce a protein or polynucleotide of interest in a target cell using the VLPs. Also described are alphavirus-based replicons that allow for expression of proteins or polynucleotides of interest in a target cell without a cytopathic effect.

Abstract: The present invention relates to glutamate dehydrogenase mutants and their application in preparation of L-phosphinothricin. The amino acid sequences of the glutamate dehydrogenase mutants are as shown in SEQ ID NO. 1˜9, 11, 13, 15, 17˜19 and 22. By means of molecular engineering, mutating the specific alanine in glutamate dehydrogenase substrate-binding pocket into glycine and/or mutating the specific valine in glutamate dehydrogenase substrate-binding pocket into alanine, the present invention has obtained NADPH-specific glutamate dehydrogenase mutants with high enzyme activity in catalyzing the substrate 2-oxo-4-[(hydroxy)(methyl)phosphinoyl]butyric acid or its salt for L-phosphinothricin preparation or NADH-specific glutamate dehydrogenase mutants with catalytic activity toward PPO; this has significantly improved substrate conversion, and increased the product concentration of the L-phosphinothricin preparation process.

Abstract: The present disclosure provides a reprosome that can induce reprogramming of a cell, in which the reprosome is characterized by including RNA of a gene involved in chromatin remodeling, in which the gene includes a kinase gene on a mitogen-activated protein kinase (MAPK) signal transduction system, and a gene having histone modification activity. The reprosome may be obtained from a stem cell difficult to process and/or from a readily obtainable somatic cell via a simple process including ultrasonic treatment. A reprogramming of one kind of a cell into another kind of a cell with a desired function can be achieved at a high efficiency in a short time via a simple treatment including a co-culturing between the reprosome and the cell. The cell thus obtained has the desired function without introduction of a chemical or foreign transcription factor into a genome and thus is more suitable for cell replacement therapies.

Abstract: The present invention concerns a method for selectively activating a thermostable hydrolase at a temperature above T1. The present invention provides compositions comprising a thermostable hydrolase and a temperature sensitive inhibitor, wherein said thermostable hydrolase and said temperature sensitive inhibitor form a hydrolase-inhibitor complex at a temperature below T1, but which dissociates at a temperature of about T1. The present invention also relates to uses of said compositions, and a method for preparing said compositions.

Abstract: Disclosed herein are a yeast strain capable of utilizing xylose as a carbon source and a method for producing lipids using the same. The yeast strain is obtained by adaptively evolving a wild-type yeast strain which cannot utilize xylose as a carbon source so that it can produce high density lipids and then transforming the adaptively evolved strain to obtain the ability to metabolize xylose. Since the strain does not have the xylose metabolic pathway based on oxidoreductase, it can produce biodiesel and biomaterials based on lipid and lignocellulosic biomass at a high yield without a problem of cofactor imbalance and can greatly improve the economic feasibility and sustainability of the production processes of biodiesel and biomaterials.

Abstract: Materials and methods related to gene targeting (e.g., gene targeting with transcription activator-like effector nucleases; “TALENS”) are provided.

Abstract: This invention relates to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) arrays and recombinant nucleic acid constructs encoding Type I-E CASCADE complexes as well as plasmids, retroviruses and bacteriophage comprising the same.

Abstract: A method for determining past exposure to chemical agents or heavy metals may include coating a capture material with a capture reagent. The capture reagent may be selected based on an ability of the capture reagent to bind with a target antibody, and the target antibody may be an indicator associated with a particular chemical agent or heavy metal. The method may further include interrogating a clinical sample associated with an individual by forming a mixture of the capture material and the clinical sample, and determining an exposure status of the individual to the particular chemical agent or heavy metal based on whether the capture material demonstrates capture of the indicator.

Abstract: Described herein, in one aspect, are antigen presenting cells (APCs) comprising an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MC class II molecules; a molecular reporter of Granzyme B (GzB) activity; and c) an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout (e.g., caspase 3 knockout). Described herein, in another aspect, is a system for detection of recognized antigen presentation by an antigen presenting cell to a cytotoxic lymphocyte or NK cell.

Abstract: The present disclosure is directed to a method of high-throughput (HTP) microbial genomic engineering, which utilizes in vivo transposon mutagenesis to develop strain libraries for the perturbation of microbial phenotypes.

Abstract: The invention relates to a method for selecting a glycopolypeptide that binds to a target protein, the method including the steps of providing a pool of glycopolypeptides fused via puromycin linker to an encoding mRNA-cDNA duplex; combining the pool with a target protein to form a mixture; incubating the mixture for a period of time sufficient to allow any target protein to bind to one or more of the glycopolypeptides, thereby forming glycopolypeptide-target protein complexes; and isolating from the mixture the glycopolypeptide-target protein complexes, thereby identifying a plurality of selected glycopolypeptides.

Abstract: Disclosed herein include methods, compositions, and systems for extending particle-associated oligonucleotides. In some embodiments, the methods of extending particle-associated oligonucleotides enable efficient methods of preparing a library of barcoded beads. It is also provided, in some embodiments, hydrogel beads degradable upon application of a chemical stimulus that comprise releasably attached oligonucleotides.

Abstract: The present invention provides methods for identifying a factor which modulates gene expression comprising providing a library of at least 1×106 nucleic acid molecules each comprising a stochastic sequence of at least 50 nucleotides, introducing said nucleic acid molecules into nucleic acid constructs which comprise a reporter sequence and which do not comprise a further separate sequence upstream of the reporter sequence that can modulate expression of the reporter sequence to generate test constructs, introducing test constructs into host cells and assessing expression of the reporter sequence, thereby to identify a factor which modulates gene expression. Libraries of nucleic acid molecules, test constructs and host cells for use in such methods are also provided.

Abstract: A transkingdom platform for the delivery of therapeutic nucleic acids to epithelial tissues where the nucleic acids are designed to have enhanced stability. The platform offers numerous improvements to prior delivery platforms including expression of the double-stranded RNA binding domain (dsRBD) domains of TAR RNA binding protein (TRBP), knockout of RNase R activity in the bacterial delivery vehicle, and expression of the methyltransferase gene, HEN1, for simultaneous packaging with a therapeutic nucleic acid delivery vehicle.

Abstract: Method for controlling for the appearance of seizures in the mammalian brain comprising modifying the abundance of a specific miRNA-miR-211, for uses in preventing seizures and providing a model system to examine the effect of a drug or a treatment to seizures.

Abstract: The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.

Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.

Abstract: The invention provides a ?-tubulin segment of a ?-tubulin gene, and also provides an application of the segment in controlling plant diseases and/or enhancing plant disease resistance, inhibiting pathogenic fungal development and pathogenicity, and improving the drug sensitivity of pathogens to tubulin binding agents. The invention also provides an in-vitro interference preparation including ?TubdsRNA segments of the above-mentioned ?-tubulin gene, and an application of the in-vitro interference preparation in breeding a transgenic plant resistant variety. The RNA interference technology of the ?-tubulin gene of the present invention has green and safe advantages of increasing the drug sensitivity of pathogenic fungi, reducing the level of drug resistance, interfering with pathogenicity, enhancing plant disease resistance, controlling a variety of plant diseases, improving the drug sensitivity to a chemical agent (carbendazim), and prolonging the dsRNAs drug retention period by the carbendazim.

Abstract: A composition for delivering cargo to cytoplasm of a cell, wherein the cargo treats sickle cell disease. In one embodiment, the composition comprises; an exosome; and cargo, located within the exosome, wherein the cargo comprises short interference RNA (siRNA) with altered single-nucleotide polymorphism SNP rs334 (A) for expressing normal hemoglobin. In another embodiment, the composition comprises: an exosome; and cargo, located within the exosome, wherein the cargo comprises a viral vector containing at least one sequence encoding normal hemoglobin comprising altered SNP rs334.

Abstract: Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have Essential Thrombocythemia (ET). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having ET.

Abstract: The invention provides methods for overcoming glucocorticoid resistance of cancers by inhibition of CASP1. Also disclosed are diagnostic methods for determining glucocorticoid resistance potential by measuring expression level or promoter methylation status of CASP1 gene and/or NLRP3 gene.